Statin use for primary prevention of cardiovascular disease among apparently healthy adults
- 24 June 2025
- journal article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Abstract
Aims: To study the association between statin adherence and the 5-year risk of major cardiovascular events among apparently healthy individuals. Methods and results: A nationwide cohort study utilizing national registries in Denmark was conducted. All apparently healthy individuals aged 40–85 years using statins for 1 year between 1997 and 2022 with no personal history of cardiovascular diseases, diabetes mellitus, chronic obstructive pulmonary disease, hepatic diseases, cancer, or parents with cardiovascular disease, among other exclusion factors, were included. Statin use was categorized according to adherence by the proportion of days covered with redeemed statin prescriptions: <50% (low), 50–75% (moderate), and 75–100% (high). The primary outcome was a composite of myocardial infarction, stroke, or cardiovascular death. The 5-year absolute risk was estimated using the Aalen-Johansen estimator while considering competing risks. Additionally, cause-specific Cox proportional hazards models were used to estimate hazard ratios across statin adherence levels. Among 151 791 apparently healthy individuals, low statin adherence was associated with a 5-year major cardiovascular risk of 4.77% (95% confidence interval 4.18–5.36). For moderate adherence, the 5-year risk was 3.71% (95% confidence interval 4.18–5.36), and the corresponding hazard ratio was 0.87 (95% confidence interval 0.75–1.01), while high adherence was associated with the lowest 5-year risk of 3.01% (95% confidence interval 2.90–3.11), and the corresponding hazard ratio was 0.66 (95% confidence interval 0.58–0.75). Conclusion: High statin adherence among apparently healthy users was associated with a significant risk reduction of major cardiovascular adverse events.Keywords
This publication has 42 references indexed in Scilit:
- Statin Use for the Primary Prevention of Cardiovascular Disease in AdultsJAMA, 2022
- Statin Use for the Primary Prevention of Cardiovascular Disease in AdultsJAMA, 2022
- Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population StudyAtherosclerosis, 2022
- Statin Discontinuation and Cardiovascular Events Among Older People in DenmarkJAMA Network Open, 2021
- Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older AdultsJACC, 2020
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood CholesterolJACC, 2019
- Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older AdultsJAMA Internal Medicine, 2017
- Appropriateness of Statins in Patients Aged ≥80 Years and Comparison to Other Age GroupsThe American Journal of Cardiology, 2012
- Adherence to Statin Treatment and Health Outcomes in an Italian Cohort of Newly Treated Patients: Results From an Administrative Database AnalysisClinical Therapeutics, 2012
- Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in ItalyClinical Therapeutics, 2010